{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T17:46:13Z","timestamp":1779903973094,"version":"3.53.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejphar.2026.178679","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:01:34Z","timestamp":1771891294000},"page":"178679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Breaking resistance in BRAF-mutant Melanoma: Novel strategies and biomarkers for optimizing targeted therapies"],"prefix":"10.1016","volume":"1019","author":[{"given":"Manar A.","family":"Al Hindawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourhan E.","family":"Omran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed H.","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya M.","family":"Alshihabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed I.","family":"El-Gamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4670-8149","authenticated-orcid":false,"given":"Hany A.","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.178679_bib1","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/cncr.35200","article-title":"A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers","volume":"130","author":"Algazi","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.ejphar.2026.178679_bib2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.tps9093","article-title":"Swog S1320: a randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAFV600E\/k mutant melanoma","volume":"33","author":"Algazi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.178679_bib3","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/s41591-020-1060-8","article-title":"Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial","volume":"26","author":"Algazi","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2026.178679_bib4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/JCO.21.02961","article-title":"Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.178679_bib5","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq Trial-ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.178679_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114048","article-title":"Genomic deletions explain the generation of alternative BRAF isoforms conferring resistance to MAPK inhibitors in melanoma","volume":"43","author":"Aya","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejphar.2026.178679_bib7","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.ejphar.2026.178679_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184436","article-title":"COMBI-r: a prospective, non-interventional study of dabrafenib plus trametinib in unselected patients with unresectable or metastatic BRAF V600-Mutant melanoma","volume":"15","author":"Berking","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejphar.2026.178679_bib9","doi-asserted-by":"crossref","first-page":"16367","DOI":"10.18632\/oncotarget.14829","article-title":"The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib\/dabrafenib-resistant melanoma cells in vitro and in vivo","volume":"8","author":"Booth","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2026.178679_bib10","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.molcel.2020.05.031","article-title":"Rational cancer treatment combinations: an urgent clinical need","volume":"78","author":"Boshuizen","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejphar.2026.178679_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104276","article-title":"The treatment of advanced melanoma: current approaches and new challenges","volume":"196","author":"Boutros","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejphar.2026.178679_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105314","article-title":"Do BRAF-targeted therapies have a role in the era of immunotherapy?","volume":"10","author":"Braden","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejphar.2026.178679_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15164026","article-title":"BRAF mutations in Melanoma: biological aspects, therapeutic implications, and circulating biomarkers","volume":"15","author":"Castellani","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejphar.2026.178679_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12935-024-03280-x","article-title":"Roles and mechanisms of aberrant alternative splicing in melanoma - implications for targeted therapy and immunotherapy resistance","volume":"24","author":"Chen","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejphar.2026.178679_bib15","doi-asserted-by":"crossref","DOI":"10.1080\/20013078.2019.1710899","article-title":"Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients","volume":"9","author":"Cordonnier","year":"2020","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.ejphar.2026.178679_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ph18081235","article-title":"Molecular basis of BRAF inhibitor resistance in melanoma: a systematic review","volume":"18","author":"Cosci","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2026.178679_bib17","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2026.178679_bib18","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2026.178679_bib19","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s11912-022-01243-x","article-title":"Triplet therapy in melanoma - combined BRAF\/MEK inhibitors and Anti-PD-(L)1 antibodies","volume":"24","author":"Dixon-Douglas","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ejphar.2026.178679_bib20","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.21.01601","article-title":"Randomized phase III trial evaluating spartalizumab plus dabrafenib and trametinib for BRAF V600-Mutant unresectable or metastatic melanoma","volume":"40","author":"Dummer","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.178679_bib21","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1186\/s12967-023-04391-1","volume":"21","author":"Dummer","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejphar.2026.178679_bib22","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-23-3171","article-title":"A proof-of-concept study of sequential treatment with the HDAC inhibitor vorinostat following BRAF and MEK inhibitors in BRAFV600-Mutated melanoma","volume":"30","author":"Embaby","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178679_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA9507","article-title":"A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT04511013)","volume":"43","author":"Eroglu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.178679_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178679_bib25","article-title":"Circulating tumor DNA monitoring in advanced mutated melanoma (LIQUID-MEL)","volume":"8","author":"Gianmarco","year":"2025","journal-title":"J. liquid Biop."},{"key":"10.1016\/j.ejphar.2026.178679_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ph18060853","article-title":"Metabolic reprogramming in Melanoma: an epigenetic point of view","volume":"18","author":"Giuliani","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2026.178679_bib27","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejphar.2026.178679_bib28","doi-asserted-by":"crossref","first-page":"270","DOI":"10.21037\/atm-23-165","article-title":"Sequence of therapies for advanced BRAFV600E\/K melanoma","volume":"11","author":"Gonzalez-Cao","year":"2023","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ejphar.2026.178679_bib29","doi-asserted-by":"crossref","first-page":"42008","DOI":"10.18632\/oncotarget.5788","article-title":"Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma","volume":"6","author":"Gray","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2026.178679_bib30","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.3390\/cells11243965","article-title":"Artificial intelligence and advanced melanoma: treatment management implications","volume":"11","author":"Guerrisi","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2026.178679_bib31","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10555-023-10097-z","article-title":"Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: the more, the better?","volume":"42","author":"Haist","year":"2023","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejphar.2026.178679_bib32","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s13046-025-03457-w","article-title":"In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibition","volume":"44","author":"Heidrich","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178679_bib33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178679_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021601","article-title":"Phenotype switching and the melanoma microenvironment; impact on immunotherapy and drug resistance","volume":"24","author":"Hossain","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178679_bib35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-025-01717-y","article-title":"Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy","volume":"18","author":"Hu","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejphar.2026.178679_bib36","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41586-025-09445-6","article-title":"Mechanical confinement governs phenotypic plasticity in melanoma","volume":"647","author":"Hunter","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.178679_bib37","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12935-022-02738-0","article-title":"Current understanding of epigenetics role in melanoma treatment and resistance","volume":"22","author":"Karami Fath","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejphar.2026.178679_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15123147","article-title":"Tumor microenvironment as a therapeutic target in melanoma treatment","volume":"15","author":"Kharouf","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejphar.2026.178679_bib39","article-title":"Adaptive therapy for metastatic melanoma: predictions from patient calibrated mathematical models","volume":"13","author":"Kim","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejphar.2026.178679_bib40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1142\/S2339547818300020","article-title":"The growing role of precision and personalized medicine for cancer treatment","volume":"6","author":"Krzyszczyk","year":"2018","journal-title":"Technology"},{"key":"10.1016\/j.ejphar.2026.178679_bib41","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-Cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J. Clin. Oncol. : Off. J. Amer. Soc. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.178679_bib42","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178679_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002995","article-title":"Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 resistance signature (IPRES)","volume":"9","author":"Lau","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejphar.2026.178679_bib44","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/pds.5630","article-title":"Real-world treatment patterns and outcomes for patients with advanced melanoma treated with immunotherapy or targeted therapy","volume":"32","author":"Lee","year":"2023","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ejphar.2026.178679_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.104969","article-title":"Single-cell RNA sequencing in melanoma: what have we learned so far?","volume":"100","author":"Lim","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejphar.2026.178679_bib46","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41467-023-36979-y","article-title":"The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma","volume":"14","author":"Lim","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2026.178679_bib47","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-CT073","article-title":"Abstract CT073: a first-in-human study of oral TNO155 (batoprotafib) alone and in combination with EGF816 (nazartinib) in adult patients with advanced solid tumors","volume":"85","author":"Lin","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178679_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105053","article-title":"Early switch from run-in with targeted to immunotherapy in advanced BRAF(V600)-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial","volume":"10","author":"Livingstone","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejphar.2026.178679_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102795","article-title":"Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma","volume":"129","author":"Loftus","year":"2024","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejphar.2026.178679_bib50","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/1078-0432.CCR-21-3382","article-title":"BAMM (BRAF autophagy and MEK inhibition in Melanoma): a phase I\/II trial of dabrafenib, trametinib, and hydroxychloroquine in advanced BRAFV600-mutant Melanoma","volume":"28","author":"Mehnert","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178679_bib51","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.annonc.2020.07.005","article-title":"ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO guidelines committee","volume":"31","author":"Michielin","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejphar.2026.178679_bib52","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1038\/s41598-022-09078-z","article-title":"AXL inhibition improves BRAF-targeted treatment in melanoma","volume":"12","author":"Nyakas","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2026.178679_bib53","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/CMR.0000000000000910","article-title":"Efficacy of local ablative therapies in patients with solid tumors treated with immune checkpoint inhibitors and oligoprogression: a single-center analysis","volume":"33","author":"Ozluk","year":"2023","journal-title":"Melanoma Res."},{"key":"10.1016\/j.ejphar.2026.178679_bib54","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1158\/0008-5472.CAN-10-2954","article-title":"PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression","volume":"71","author":"Paraiso","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178679_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020482","article-title":"Current advances in the treatment of BRAF-mutant melanoma","volume":"12","author":"Patel","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejphar.2026.178679_bib56","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/24726303211008858","article-title":"Toxicity of combinations of kinase pathway inhibitors to normal human cells in a three-dimensional culture","volume":"26","author":"Rafsanjani Nejad","year":"2021","journal-title":"SLAS Technol"},{"key":"10.1016\/j.ejphar.2026.178679_bib57","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.celrep.2015.09.037","article-title":"New functional signatures for understanding melanoma biology from tumor cell lineage-specific analysis","volume":"13","author":"Rambow","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejphar.2026.178679_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24044014","article-title":"Metastatic melanoma: liquid biopsy as a new precision medicine approach","volume":"24","author":"Ricciardi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178679_bib59","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178679_bib60","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(25)00133-0","volume":"26","author":"Robert","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2026.178679_bib61","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1038\/s41467-024-47280-x","article-title":"Single-cell multiomics reveals the interplay of clonal evolution and cellular plasticity in hepatoblastoma","volume":"15","author":"Roehrig","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2026.178679_bib62","doi-asserted-by":"crossref","first-page":"273","DOI":"10.21037\/atm-2022-78","article-title":"Triple combinations of immunotherapy and targeted therapy in patients with melanoma with brain metastases","volume":"11","author":"Rutkowski","year":"2023","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ejphar.2026.178679_bib63","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1158\/1078-0432.CCR-15-0321","article-title":"Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials","volume":"22","author":"Santiago-Walker","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178679_bib64","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2217\/fon-2021-1486","article-title":"STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic\/unresectable BRAF V600-mutant melanoma","volume":"18","author":"Schadendorf","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejphar.2026.178679_bib65","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1200\/JCO.23.01136","article-title":"Systemic therapy for melanoma: ASCO guideline update","volume":"41","author":"Seth","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.178679_bib66","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1200\/OP.23.00675","article-title":"Systemic therapy for melanoma: ASCO guideline update Q and A","volume":"20","author":"Sondak","year":"2024","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.ejphar.2026.178679_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.046","article-title":"LBA52 A randomized phase Ib\/II study of the selective small molecule AXL inhibitor bemcentinib in combination with either dabrafenib\/trametinib or pembrolizumab in patients with metastatic melanoma","volume":"34","author":"Straume","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejphar.2026.178679_bib68","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/2159-8290.CD-17-1119","article-title":"First-in-Class ERK1\/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study","volume":"8","author":"Sullivan","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejphar.2026.178679_bib69","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s12013-024-01340-7","article-title":"Shedding light on the role of exosomal PD-L1 (ExoPD-L1) in cancer progression: an update","volume":"82","author":"Sun","year":"2024","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.ejphar.2026.178679_bib70","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/2159-8290.CD-21-0554","article-title":"Tissue-agnostic drug development: a new path to drug approval","volume":"11","author":"Thein","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejphar.2026.178679_bib71","first-page":"95","article-title":"Phase I\/II trial of concurrent extracranial palliative radiation therapy with dabrafenib and trametinib in metastatic BRAF V600E\/K mutation-positive cutaneous melanoma","volume":"30","author":"Wang","year":"2021","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"10.1016\/j.ejphar.2026.178679_bib72","first-page":"58","article-title":"Patient preferences for treatment of advanced melanoma: impact of comorbidities","volume":"19","author":"Weilandt","year":"2021","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"10.1016\/j.ejphar.2026.178679_bib73","article-title":"Stereotactic body radiotherapy for oligoprogression with or without switch of systemic therapy","volume":"45","author":"Willmann","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"10.1016\/j.ejphar.2026.178679_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17030480","article-title":"Evaluating tumour mutational burden as a key biomarker in personalized cancer immunotherapy: a pan-cancer systematic review","volume":"17","author":"Zgura","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejphar.2026.178679_bib75","doi-asserted-by":"crossref","first-page":"73817","DOI":"10.18632\/oncotarget.12074","article-title":"SHP2 phosphatase as a novel therapeutic target for melanoma treatment","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926001615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926001615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:55:40Z","timestamp":1779425740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926001615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":75,"alternative-id":["S0014299926001615"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178679","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breaking resistance in BRAF-mutant Melanoma: Novel strategies and biomarkers for optimizing targeted therapies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178679","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178679"}}